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 Background Integrin αvβ6 promotes migration, invasion, and survival of cancer cells; however, the relevance and role of αvβ6 
has yet to be elucidated in breast cancer.
 Methods Protein expression of integrin subunit beta6 (β6) was measured in breast cancers by immunohistochemistry 
(n > 2000) and ITGB6 mRNA expression measured in the Molecular Taxonomy of Breast Cancer International 
Consortium dataset. Overall survival was assessed using Kaplan Meier curves, and bioinformatics statistical 
analyses were performed (Cox proportional hazards model, Wald test, and Chi-square test of association). Using 
antibody (264RAD) blockade and siRNA knockdown of β6 in breast cell lines, the role of αvβ6 in Human Epidermal 
Growth Factor Receptor 2 (HER2) biology (expression, proliferation, invasion, growth in vivo) was assessed by 
flow cytometry, MTT, Transwell invasion, proximity ligation assay, and xenografts (n ≥ 3), respectively. A  stu-
dent’s t-test was used for two variables; three-plus variables used one-way analysis of variance with Bonferroni’s 
Multiple Comparison Test. Xenograft growth was analyzed using linear mixed model analysis, followed by Wald 
testing and survival, analyzed using the Log-Rank test. All statistical tests were two sided.
 Results High expression of either the mRNA or protein for the integrin subunit β6 was associated with very poor survival 
(HR = 1.60, 95% CI = 1.19 to 2.15, P = .002) and increased metastases to distant sites. Co-expression of β6 and HER2 
was associated with worse prognosis (HR = 1.97, 95% CI = 1.16 to 3.35, P = .01). Monotherapy with 264RAD or 
trastuzumab slowed growth of MCF-7/HER2-18 and BT-474 xenografts similarly (P < .001), but combining 264RAD 
with trastuzumab effectively stopped tumor growth, even in trastuzumab-resistant MCF-7/HER2-18 xenografts.
 Conclusions Targeting αvβ6 with 264RAD alone or in combination with trastuzumab may provide a novel therapy for treating 
high-risk and trastuzumab-resistant breast cancer patients.
  JNCI J Natl Cancer Inst (2014) 106(8): dju169 doi:10.1093/jnci/dju169
One of the most aggressive subtypes of breast cancer is caused 
by overexpressed Human Epidermal Growth Factor Receptor 2 
(HER2), a member of the receptor tyrosine kinase family of recep-
tors comprising of HER1-HER4 (1). HER2 is overexpressed in 
25–30% of breast cancer (1,2) and imparts a more invasive pheno-
type, although the mechanisms are not clear (3). Introduction of the 
antibody trastuzumab (TRA), which blocks downstream signaling 
from HER2, reduces recurrence and mortality in HER2-positive 
(HER2+) breast cancer patients (4,5). Unfortunately, over 70% of 
patients either have de novo or develop resistance to trastuzumab, 
leaving them without suitable treatment options (6). Thus, identi-
fying improved therapies for women with HER2+ breast cancer is 
essential.
Studies have implicated dysregulation of the PI3K/Akt path-
way as a resistance mechanism in HER2+ breast cancer (7). 
However, Akt is involved in many non-cancer related pathways, 
hence inhibition may lead to off-target and potentially undesir-
able effects (8). Specifically, how HER2 promotes invasion and 
how PI3K signaling promotes trastuzumab-resistance must be 
discovered.
TGFβ promotes HER2-driven cancer by increasing migration, 
invasion, and metastasis (9–11). However, TGFβ exists in tissues as 
a latent form and must become activated before inducing biological 
activity (12). A major activator of TGFβ is the integrin αvβ6 (13), 
which is implicated in promoting multiple types of cancer (14–18), 
including the progression from ductal carcinoma in situ (DCIS) to 
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invasive carcinoma in the breast (19). For this reason, we consid-
ered whether αvβ6 could influence HER2+ breast cancer.
Integrins are a family of 24  αβ heterodimeric transmembrane 
cell-surface receptors that modulate cell behavior, transducing spatio-
temporal messages from the extracellular environment (20). Integrin 
functions include adhesion, migration, invasion, growth, survival, and 
differentiation. Dysregulation of integrin expression and/or signaling 
correlates with development of cancer through inappropriately regu-
lating the processes above, but also mediating invasion and metastasis 
(21). The integrin αvβ6, expressed only by epithelial cells, is usually 
only detectable on cells undergoing tissue remodeling, including 
wound healing and cancer (17). Integrin αvβ6 promotes invasion of 
carcinoma cells and its overexpression correlates with poor survival 
from colon, cervix, and non-small-cell lung cancer (14–16).
In this study, we examine expression and function of αvβ6 in 
breast cancer in vitro and in vivo. We show that high αvβ6 expression 
is not only an independent predictor of overall survival from breast 
cancer associated with distant metastases, but that it is a tractable 
target for antibody therapy. Thus, simultaneous antibody targeting 
of αvβ6 and HER2 in mice bearing breast cancer xenografts statisti-
cally significantly improved the therapeutic efficacy of trastuzumab, 
including eliminating trastuzumab-resistant tumors. These data 
suggest that targeting αvβ6 may improve trastuzumab therapy and 
potentially be effective against tumors that are trastuzumab resistant.
Methods
Clinical Samples and Immunohistochemical Analysis
Two independent cohorts of breast cancer samples were analyzed follow-
ing REMARK guidelines (22). One comprised 1795 consecutive cases 
from the Nottingham Tenovus Breast Carcinoma Series (Nottingham 
Cohort) of women younger than 70 presenting from 1986–1998 
(23,24). Data were available on tumor type, histological grade, size, 
lymph node (LN) status, ER-, PR- and HER2-status, cytokeratin (CK) 
profile, recurrence (local, regional, and distant), and survival. The sec-
ond cohort constituted 1197 invasive cases from Guy’s and St.Thomas’ 
Breast Tissue Bank, London (London Cohort). Patients underwent sur-
gery from 1960–1998 (98% from 1975 onwards). Data were available 
on tumor type, grade, LN status, ER-, PR- and HER2-status, disease 
free survival, and overall survival. A summary of clinicopathological data 
is presented (Supplementary Table 1, available online). All studies were 
approved by the North East London Research Ethics Committee with 
written informed patient consent obtained.
 Immunohistochemistry utilized 4 μm, formalin-fixed, paraffin-
embedded serial sections of tissue microarrays (TMAs). The proto-
col used for αvβ6 integrin (mAb 6.2G2, Biogen Idec) was described 
previously (15).
Transwell and Organotypic Invasion Assays
Transwell invasion assays: 5x104 cells (Figure 2B) were seeded per well 
post-treatment into 6.5 mm diameter, 8  μm pore-sized Transwells 
(Corning BV) coated with 70 μl BD Matrigel Basement Membrane 
matrix (Matrigel):media (1:2 ratio). Cells that invaded through Matrigel 
were counted after 72 hours using a CASY counter (Scharfe Systems, 
Germany). Organotypic assays were prepared as described previously 
but were adapted to Transwells (19); breast cancer cells were seeded per 
well posttreatment into Transwell gel mix containing MRC5/hTERT 
fibroblasts. Gels were fixed in formal saline after 5 to 6 days, paraffin 
embedded and sections hematoxylin and eosin stained. Invasion Index 
was calculated by multiplying the mean depth at 5 points on each gel by 
the area occupied by the invading cells using ImageJ 1.64 software (NIH).
Human Tumor Xenograft Models
All mouse experiments followed Home Office Guidelines deter-
mined by the Animals (Scientific Procedures) Act 1986. For all mouse 
studies, 264RAD and trastuzumab were dissolved in phosphate-buff-
ered saline (PBS), at a final concentration of 10 mg/kg. Estrogen pel-
lets (0.25 mg 60-day release, Innovative Research of America) were 
implanted subcutaneously into mice 24 hours prior to tumor cell injec-
tion. Female SCID-mice (6 to 8 weeks of age; with n ≥ 3/treatment; 
generous gift from Oncology iMED, AstraZeneca, Maccelsfield, UK) 
or female CD1 nu/nu mice (Charles River Laboratories) were inoc-
ulated subcutaneously with either 1x106 MCF-7/HER2-18 cells in 
200 μl of PBS or 1x107 BT-474 cells in 1:1 PBS/Matrigel. Mice were 
randomized into treatment groups based on tumor volume (n ≥ 3/
treatment). Mice received biweekly intraperitoneal injections (10 mg/
kg in 200 µl of PBS) of human immunoglobulin (IgG), 264RAD, tras-
tuzumab, or both 264RAD and trastuzumab. Tumors were measured 
with calipers biweekly in two directions and tumor volume calculated 
using the formula (width2 x length)/2. For further details, see the 
Supplementary Methods, avaible online.
Statistical Analyses
All statistical tests were two sided. A P value of less than .05 was 
considered statistically significant.
Preclinical Data. Statistical significance in drug-treated vs control in 
vitro cultures was determined using the Student’s t-test for two vari-
ables. For three or more variables, data were analyzed using one-way 
analysis of variance (ANOVA) with Bonferroni’s Multiple Comparison 
Test using Prism GraphPad software (Systat Software, San Jose, CA). 
For tumor xenograft models, individual growth curves were plotted, 
and then a linear mixed model was used to test for differences between 
the treatments (25). It was fitted by maximum likelihood using the 
nlme package in the statistical software R (R Development Core 
Team, 2010) 2.11.1. P values are from Wald tests. Survival of mice was 
measured using the Log-Rank test in Prism GraphPad. Error bars in 
all experiments represent 95% confidence intervals (CIs).
Clinical Data. HER2+ patients in the London and Nottingham 
clinical cohorts were dichotomized into low- and high-risk groups 
using αvβ6 protein expression (low-risk αvβ6 < 5, high-risk αvβ6 ≥ 
5). Survival analysis was performed in R statistical environment 
v.2.14.1 (R package: survival v2.36-14). Hazard ratio was estimated 
by fitting Cox proportional hazards model, and statistical significance 
of the difference between the survival of risk groups was estimated 
using the Wald test. Proportional hazards assumption was tested by 
assessing correlation between survival times (5-year follow-up) and 
Schoenfeld residuals of αvβ6/ITGB6-dervied risk group variable, 
followed by Chi-square test (two-sided P < .001).
Survival Analysis. A Chi-square test of association between sub-
groups and deaths was performed to determine any differences 
across subgroups of each variable. The P value representing the 
statistical significance of the association is included in Table 1.
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A multivariable Cox model adjusted for all covariates was fit to 
include node status, triple negative and HER2 covariates, in order 
to confirm that β6 is an independent predictor of breast cancer 
survival. There was no grade analysis, because the London cohort 
does not have this information. Please also note that triple negative 
(TN) status and HER2 status is not included, because we cannot 
have TN samples in the HER2 cohort, and HER2 status is not 
applicable, as all samples are HER2+. Multivariable analyses were 
also performed with cohort as a controlling factor for each covari-
ate (Supplementary Table 3, available online).
Likewise, gene expression-derived HER2+ patients in 
the Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) cohort (26) were analyzed using 
the ITGB6 expression profile. The risk-group dichotomization 
threshold for ITGB6 expression in METABRIC was established 
by using the proportion of low- and high-risk HER2+ patients, 
determined by antibody studies of the London/Nottingham 
cohorts. Kaplan Meier survival curves were drawn in R statisti-
cal environment v2.14.1.
Please see the Supplementary Methods (available online) for 
additional detailed methods used in this study.
results
Analysis of Integrin αvβ6 and HER2 Coexpression in 2000 
Breast Cancer Patient Samples
We stained for αvβ6 expression (Figure 1A) on TMAs from two 
separate cohorts (London and Nottingham) totaling over 2000 
women with breast cancer. The clinicopathological parameters and 
the association of αvβ6 expression with these parameters are shown 
in Supplementary Tables 1 and 2 (available online). Normal breast 
tissue (n > 15) lacked αvβ6 expression, whereas high expression of 
αvβ6 was observed on 15% to 16% of invasive ductal carcinoma 
(Figure 1, A and B; Supplementary Table 2, available online). There 
was a statistically significant association between high expression of 
αvβ6 and poor survival (Figure 1, C and D). Thus, 5-year overall 
survival (OS) dropped from 75.6% to 58.8% in the London cohort 
(Figure  1C; Hazard ratio (HR)  =  1.99, 95% CI  =  1.48 to 2.66, 
P < .001) and from 84.1% to 75.0% in the Nottingham cohort 
(Figure 1D; HR = 1.73, 95% CI = 1.26 to 2.37, P < .001), and this 
statistically significant association between OS and high expression 
of αvβ6 extended for at least 10 years (Supplementary Figure 1, 
available online). After adjusting for tumor stage, size, grade, and 
cohorts (Table 1; Supplementary Table 3, available online), αvβ6 
remained an independent predictor of OS (HR  =  1.60, 95% 
CI = 1.19 to 2.15, P = .002). No grade was available for the London 
cohort, hence this analysis was not possible.
Tumor dissemination data were available only for the Nottingham 
series, in which αvβ6 expression associated statistically significantly 
with distant spread (P = .02). Of 1026 αvβ6-negative cases, 317 (30.9%) 
had distant metastases, whereas of the corresponding 205  αvβ6-
positive cases 81 (39.5%) had distant metastases. Furthermore, αvβ6-
positive cancers were more likely to have spread to bone (P = .04).
We also noted a strong association between HER2 and high 
αvβ6 expression (P  =  .001; Supplementary Table  2, available 
online). Coexpression of high αvβ6 and HER2 proteins statisti-
cally significantly reduced overall survival in the combined London 
and Nottingham cohorts (Figure 1E; HR = 1.58, 95% CI = 1.11 to 
2.25, P = .01), which remained statistically significant after adjust-
ment for clinical covariates (HR  =  1.97, 95% CI  =  1.16 to 3.35, 
P =  .01; Table 1). Increased risk may be controlled transcription-
ally, because analysis of the METABRIC Breast cancer expression 
database (n = 238 HER2+ cases) (26) confirmed that patients who 
had high ERBB2 (HER2) and ITGB6 (integrin β6 subunit) gene 
expression had statistically significantly reduced survival (Figure 1F; 
HR = 1.99, 95% CI = 1.28 to 3.10, P = .002). Thus, we investigated 
whether HER2 and αvβ6 cooperated to promote breast cancer.
Effect of Integrin αvβ6 and HER2 Blockade on Breast 
Carcinoma Invasion
We screened (by flow cytometry) 20 breast cancer cell lines for expres-
sion of αvβ6 and HER2 and their ability to invade through Matrigel 
(Figure 2, A and B; Supplementary Table 4, available online). 80% 
of cell lines expressed αvβ6, and of these we examined more closely 
αvβ6/HER2 double-positive cell lines BT-474, MCF10A.CA1a 
(CA1a), and trastuzumab-resistant MCF-7/HER2-18 (HER2-18). 
Table 1. Five-year truncated overall survival
Factor HR (95% CI) P*
All Patients
 αvβ6 1.60 (1.19 to 2.15) .002
 Cohort 1.40 (1.03 to 1.89) .03
 ER 0.77 (0.49 to 1.19) .24
 PR 0.69 (0.50 to 0.96) .03
 HER2 1.84 (1.24 to 2.72) .002
 Triple negative 1.36 (0.81 to 2.31) .25
 Stage 1 (baseline)
 Stage 2 2.00 (1.48 to 2.69) <.001
 Stage 3 3.46 (2.12 to 5.67) <.001
 Stage 4 3.99 (0.90 to 17.67) .07
 Stage 5 4.62 (1.40 to 15.22) .01
 Node 1 (baseline)
 Node 2 1.81 (1.19 to 2.75) .005
 Node 3 3.11 (1.92 to 5.02) <.001
 Tumor size 1 (baseline)
 Tumor size 2 1.80 (1.31 to 2.44) <.001
 Tumor size 3 1.54 (0.91 to 2.61) .11
HER2+ cohort only
 αvβ6 1.97 (1.16 to 3.35) .01
 Cohort 1.86 (1.02 to 3.38) .04
 ER 0.55 (0.30 to 1.00) .05
 PR 1.38 (0.71 to 2.67) .34
 Stage 1 (baseline)
 Stage 2 2.72 (1.41 to 5.25) .003
 Stage 3 3.05 (1.23 to 7.55) .02
 Stage 4 7.12 (0.78 to 64.84) .08
 Stage 5 3.00 (0.33 to 27.60) .33
 Node 1 (baseline)
 Node 2 2.18 (1.09 to 4.35) .03
 Node 3 4.55 (2.07 to 10.00) <.001
 Tumor size 1 (baseline)
 Tumor size 2 1.73 (0.89 to 3.35) .11
 Tumor size 3 1.59 (0.61 to 4.11) .34
* A Chi-square test of association between subgroups and deaths was 
performed to determine any differences across subgroups of each variable. 
Multivariable Cox model adjusted for all covariates was fit to include node 
status, triple negative, and HER2 covariates in order to confirm that β6 is an 
independent predictor of breast cancer survival. There was no grade analysis, 
because the London cohort does not have this information. ER = estrogen 
receptor; PR = progesterone receptor.
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Antibody blockade of αvβ6 (264RAD) or HER2 (TRA), or siRNA 
to ITGB6 or ERBB2, blocked invasion statistically significantly 
(Figure 2, C–F). Because 264RAD blocks αvβ8, we repeated these 
experiments with the αvβ6-specific antibody, 10D5, with similar 
results (Supplementary Figure  2A, available online), confirming 
invasion was αvβ6-dependent. Combining antibodies to αvβ6 and 
HER2 did not decrease invasion more than single antibody block-
ade (Figure 2G), possibly suggesting that these receptors functioned 
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Figure 1. Coexpression of integrin αvβ6 and HER2 and overall survival in 
breast cancer patients. Kaplan–Meier curves by integrin αvβ6 expression 
status. Tick marks indicate patients who were still alive at the time of anal-
yses or who were censored. All P values refer to Wald tests as determined 
by the Multivariable Cox model. All tests were two sided. A) Normal 
and B) cancerous breast cancer tissue sections immunohistochemically 
stained for integrin αvβ6 (brown staining) using 6.2G2 antibody (Biogen 
Idec). Magnification x10, scale bar  =  100  μM. Overall survival in two 
cohorts of breast cancer patients from London (C) and Nottingham (D) by 
integrin αvβ6 status (high expression represented by a dashed line, low 
represented by a solid line). The P value for patients with high integrin 
αvβ6 vs low expression in tumors is <.001. E) Overall survival of HER2+ 
patients from the combined London and Nottingham patient cohorts 
by integrin αvβ6 status. The P value for patients with high integrin αvβ6 
status versus low tumors is <.001. F) Overall survival of HER2+ (ERBB2) 
patients from the Molecular Taxonomy of Breast Cancer International 
Consortium (METABRIC) cohort by integrin αvβ6 status. The survival of 
patients with high ITGB6-expressing tumors vs low-expressing tumors is 
significantly lower (P = .003). Please also see Supplementary Tables 1–3 
and Supplementary Figure 1 (available online). OS = overall survival.
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Figure 2. Integrin αvβ6 and HER2-blockade and breast cancer cell inva-
sion. A) Expression of integrin αvβ6 and HER2 in a breast cancer cell line 
panel assessed by flow cytometry. Isotype controls all showed lower 
expression nearer the y-axis side, while integrin αvβ6 and HER2 expres-
sion shift the curves to the right (see Supplementary Table 4, available 
online, for full panel of cell lines analyzed). B) Transwell invasion assay 
of breast cancer cell lines expressing varying levels of integrin αvβ6 
and HER2. 5 x 104 cells/well were seeded and the number of cells that 
invaded was counted after 72 hours. C and D) Breast cancer cell-line 
invasion is integrin αvβ6 dependent. Cells were subjected to either 30 
minutes of incubation with IgG or αvβ6 blocking antibody (β6 Ab) (10 μg/
mL) (C) or 72 hours of transfection with control or β6 siRNA (20μM) (D) 
and subjected to a Transwell invasion assay as before. E and F) Breast 
cancer cell-line invasion is HER2 dependent. Cells were pretreated for 
30 minutes with IgG or Trastuzumab (TRA) (10 μg/mL) (E) or transfected 
for 72 hours with control or HER2 siRNA (20μM) (F) and subjected to a 
Transwell invasion assay. G) Cells were pretreated for 30 minutes with 
IgG, β6 Ab, TRA (all 10 μg/mL), or a combination of the blocking antibod-
ies, and subjected to a Transwell invasion assay. All experiments were 
performed in triplicate, representative experiments shown (n = 6, error 
bars represent 95% confidence interval). *P = .05, **P = .01, ***P < .001, 
relative to IgG or control-treated cells. C-F; Student’s t-test, B and G; 
one-way analysis of variance with Bonferroni’s Multiple Comparison 
Test. All tests were two sided. Please also see Supplementary Figure 2, 
available online. HER2 = Human Epidermal Growth Factor Receptor 2; 
IgG = immunoglobulin; TRA = trastuzumab.
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through the same pathway. Proliferation was not statistically sig-
nificantly changed by any treatment over 3 days in the presence or 
absence of Matrigel (Supplementary Figure 2, B and C).
Confocal microscopy revealed αvβ6 and HER2 colocalized in 
breast cancer cells (Supplementary Figure  3A, available online). 
Although the two proteins did not coimmunoprecitate, with or 
without Heregulin β1 (HRGβ) stimulation (data not shown), a 
proximity ligation assay revealed that the receptors do exist in close 
proximity (Supplementary Figure 3C, available online), suggesting 
they are part of the same molecular complex.
Investigating Whether Integrin αvβ6 Mediates HER2-
Driven Invasion
HRGβ was added to cells to induce HER2/3 heterodimerization 
and downstream signaling. HER2/HER3 is the preferred heter-
odimer in breast cancer (27). Figures 3A and 3B show that HRGβ 
statistically significantly increased the invasive propensity of both 
HER2-18 and CA1a cells, and this increased invasion could be 
inhibited by HER2 (trastuzumab) or αvβ6 (264RAD) blockade. 
These data suggest that HER2-promoted invasion is mediated by 
αvβ6. The addition of HRGβ to BT-474 cells did not enhance inva-
sion, suggesting their HER2-promoted invasive propensity was at a 
maximum. However, blockade of αvβ6 or HER2 suppressed their 
endogenous invasion (Figure 3, A and B).
We tested our cell lines using the organotypic invasion assay, 
which allows tumor cells to invade into a fibroblast-rich colla-
gen gel mimicking the tumor:stroma interface. HER2-18 and 
BT-474 cells could not be adapted to the organotypic system, so 
we tested CA1a cells. Figure 3C shows both antibody blockade 
and siRNA knockdown of β6 or HER2 suppressed invasion statis-
tically significantly. Invasion was reduced by 67.5% (SD = 12.5%) 
with αvβ6-blockade (relative to IgG/control, P  =  .002, 95% 
CI = 58.68% to 206.40%) and 69.8% (SD = 9.9%) with HER2 
blockade (relative to IgG/Control, P =  .002, 95% CI = 36.31% 
to 184.10%) (invasion quantified as ‘Invasion Index’ shown in 
histograms). These data suggest that in breast cancer, αvβ6 may 
cooperate with HER2 to regulate intracellular signals required 
for invasion, and αvβ6-blockade could improve HER2-targeted 
antibody therapy.
Antibody Blockade of αvβ6 Combined with Trastuzumab 
in Human Breast Xenografts
We tested the effect of 264RAD on the growth of trastuzumab-
sensitive BT-474 xenografts. Two-week treatment of mice bearing 
BT-474 tumors of 100 mm3 with 264RAD stopped tumor growth, 
compared with IgG (P < .001), whereas trastuzumab reduced the 
growth of tumors by 77.8% (P < .001) (Figure 4A). Combination of 
264RAD and trastuzumab was more effective and reduced tumor 
volume by 94.8%, compared with IgG (P < .001).
To assess whether αvβ6-blockade could improve the efficacy 
of trastuzumab, we repeated antibody therapy with trastuzumab-
resistant HER2-18 xenografts. Figure 4B shows that in compari-
son with IgG, monotherapy with either 264RAD or trastuzumab 
slowed growth by 53.9% (P < .001) and 52.1% (P < .001), respec-
tively, whereas combination therapy reduced tumor volume by 
76.2% (P < .001). Representative images of BT-474 and HER2-18 
excised xenografts are shown in Figure 4C.
Molecular Response of Breast Tumors to 264RAD and 
Trastuzumab
Residual BT-474 and HER2-18 xenografts post-two-week anti-
body treatment were analyzed for expression of target and signaling 
molecules. Figure 4D (quantified in Figure 4E) shows treatment 
of BT-474 xenografts (n = 3) with 264RAD or trastuzumab hav-
ing statistically significantly reduced expression of β6, compared 
with IgG (95% CI = 0.02 to 0.42, P = .04; 95% CI = 0.02 to 0.41, 
P = .068, respectively), whereas combination almost abolished β6 
expression, compared with IgG (95% CI = 0.20 to 0.41, P = .001).
Combination therapy additionally reduced expression of HER2, 
HER3, and Smad2. Combination therapy, but not monotherapy, 
was required to suppress Akt2 expression, suggesting that αvβ6 and 
HER2 coregulate this PI3K effector.
Similar results were seen in HER2-18 xenografts (Figure  4, 
F-G). Again, statistically significant reduction in T-Akt2 required 
combination therapy and 264RAD-increased HER2 expression, 
further suggesting that αvβ6 and HER2 cooperate.
Tumor/Stroma Biomarkers of 264RAD and Trastuzumab 
Combination Therapy
We immunostained tumor xenografts from two-week treatment 
studies (Figure 4). Figures 5 and 6 show micrographs of BT-474 
and HER2-18 xenografts stained for pancytokeratin (CK) in order 
to detect the epithelial (tumor) cells, Ki67 (proliferation), β6 and 
HER2 (antibody targets), endomucin (blood vessels), and α-sma 
(α-smooth muscle actin;myofibroblasts). BT-474 xenografts were 
also assessed for cleaved-caspase 3 as a marker of apoptosis (HER2-
18 cells do not express this caspase). Most prominent anti-tumor 
effects were observed with combination therapy (Figures 4 and 7), 
thus analysis concentrated on these treatments.
Compared with IgG, combination therapy of BT-474 tumors 
induced statistically significant loss of tumor (CK+) cells, which 
were replaced (by >95%; Figure  5) by a mostly proteinaceous 
stroma (P < .05, combination therapy vs IgG). Because most of the 
tumor was lost, analysis of other markers was only in CK+ areas. 
Compared with IgG, combination therapy reduced tumor expres-
sion of β6 (P  =  .01), HER2 (P  =  .017), and proliferation (Ki67, 
P = .017); stromal vasculature (endomucin, P = .033) and myofi-
broblasts (α-sma, P  =  .014) were also statistically significantly 
suppressed (Figure  5). Apoptosis (cleaved-caspase 3)  was also 
statistically significantly increased with combination treatment 
(P = .039, compared with IgG) offering an additional mechanism 
for BT-474 cell loss.
Combination treatment had a statistically significant effect on 
β6, HER2, endomucin and α-sma expression in HER2-18 xeno-
grafts (Figure 6). Ki67 expression was unaltered.
Our data suggest the tumor-suppressive effect of combination 
treatment is due to a combined effect on both tumor and stromal 
cells (Figure 4, A and B).
Effect of Long-term Combination Therapy in a 
Trastuzumab-Tesistant Model
Mice bearing HER2-18 xenografts of palpable size (10 to 20 mm3) 
were given six weeks of antibody therapy. 264RAD reduced growth 
by greater than 70% compared with IgG, equivalent to the reduc-
tion seen with trastuzumab (both P < .001, Figure 5A). However, 
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Figure  3. Role of integrin αvβ6 in HER2-driven breast cancer cell-line 
invasion. Cells were pretreated for 30 minutes with IgG, HRGβ (1μM) 
in the presence and absence of αvβ6 blocking antibody (10 μg/mL) (A) 
or trastuzumab (TRA) (10 μg/mL) (B) and 5 x 104 cells/well seeded into 
a Transwell invasion assay. The number of cells invaded was counted 
after 72 hours. All experiments were performed in triplicate, representa-
tive experiments shown (n  =  6, error bars represent 95% confidence 
interval). *P  =  .05, **P  =  .01, ***P < .001 (relative to IgG, two-sided, 
one-way analysis of variance (ANOVA) with Bonferroni’s Multiple 
Comparison Test). C) Organotypic invasion of MCF10.CA1a (CA1a) 
cell line. Cells were pretreated for 30 minutes with IgG, αvβ6 blocking 
antibody or TRA (10 μg/mL) or transfected with siRNA to αvβ6 or HER2 
for 72 hours (20μM) prior to seeding. Gels were fixed in formal saline 
after 5 to 6 days incubation, paraffin embedded, sectioned and sections 
stained with H&E. Magnification bar = 10 μM. Histograms quantify the 
invasion of each cell with the aforementioned treatments as invasion 
index (n = 3, error bars represent 95% confidence interval). Experiments 
were performed in triplicate (n = 2/experiment), representative experi-
ments shown. *P = .05, **P = .01, ***P < .001 (relative to Control siRNA 
treated cells, two-sided, one-way ANOVA with Bonferroni’s Multiple 
Comparison Test). HER2 = Human Epidermal Growth Factor Receptor 2; 
IgG = immunoglobulin; TRA = trastuzumab.
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Figure  4. The effect of 264RAD in combination with trastuzumab on 
human breast cancer xenograft growth in SCID mice. A) Mice bear-
ing human BT-474 tumors were treated with IgG (square, solid line), 
264RAD (triangle, dashed line, in line with TRA treatment), trastu-
zumab (TRA) (square, dashed line), or 264RAD+TRA (triangle on lower 
dashed line) (10 mg/kg; ip) twice weekly for two consecutive weeks 
(start of treatment indicated by arrow, day 0). Data are presented 
as mean tumor volume (error bars represent 95% confidence inter-
val, n ≥ 4 mice/group). Treatment commenced when tumors reached 
100 mm3. B) Mice bearing human HER2-18 tumors were treated as in 
(A). (C) Photographic images of representative BT-474 and HER2-18 
xenografts posttreatment outlined in (A). Magnification bar  =  5 mm. 
D) BT-474 xenograft protein expression. Xenografts were treated as 
in (A), harvested, protein extracted, and subjected to immunoblot-
ting. Blots were probed for indicated proteins. E) Histograms of rela-
tive protein expression from blots shown in (D) determined by optical 
density (n = 3 individual tumors, error bars represent 95% confidence 
interval). *P =  .05, **P =  .01, ***P < .001 (relative to IgG or to treat-
ment indicated by corresponding lines to the side of growth curves 
and above histograms, as determined by plotting individual growth 
curves and then applying a linear mixed model to test for differences 
between treatments [A and B], and two-sided, one-way analysis of vari-
ance with Bonferroni’s Multiple Comparison Test [E and G]). F and G) 
HER2-18 xenograft protein expression and quantification as outlined in 
(D and E). HER2  =  Human Epidermal Growth Factor Receptor 2; 
IgG = immunoglobulin; TRA = trastuzumab.
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Figure  5. The effect of 264RAD in combination with trastuzumab on 
human xenograft BT-474 tumor growth and stroma. A) Micrographs of 
BT-474 tumor xenografts from mice treated with IgG or 264RAD+TRA 
(10 mg/kg; ip) twice weekly for two consecutive weeks (tumors har-
vested after two weeks of treatment from Figure  4A). Tumors were 
harvested, fixed, parafin embedded, and sections subjected to immuno-
histochemical staining for the indicated molecules of interest, including 
pancytokeratin (CK, epithelial marker), Ki67 (proliferation), endomucin 
(vasculature), α-sma (myofibroblast), cleaved caspase 3 (apoptosis), as 
well as αvβ6 and HER2 expression. Representative images are shown 
of the three tumors harvested for IgG and the combination treatment, 
where the greatest effect was observed. Scale bar in whole tumor 
images = 1000 μM, magnified images (x60) are of indicated region of 
interest (CK+ cells). Scale bar in x60 magnification images  =  20  μM. 
B) Bar graph of composition of xenografts (% CK+ cells = white bar, 
% necrotic area in black, and % stroma is in gray or blue) and his-
tograms of specific marker expression of xenografts shown in (A). 
Assessed and scored by two individuals (n = 3 individual tumors, error 
bars represent 95% confidence interval). *P  =  .05, **P  =  .01, ***P < 
.001 (relative to IgG, as determined by two-sided, one-way analysis of 
variance with Bonferroni Multiple Comparison Test [B, upper panel] 
and two-sided Student’s t-test [B, lower panel]). CK = pancytokeratin; 
HER2 = Human Epidermal Growth Factor Receptor 2; IgG =  immuno-
globulin; TRA = trastuzumab.
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Figure  6. The effect of 264RAD in combination with trastuzumab 
on human xenograft MCF-7/HER2-18 tumor growth and stroma. A) 
Micrographs of MCF-7/HER2-18 tumor xenografts from mice treated 
with IgG, or 264RAD+TRA (10 mg/kg; ip) twice weekly for two con-
secutive weeks (tumors harvested after two weeks treatment from 
Figure 4B). Tumors were harvested, fixed, parafin embedded, and sec-
tions subjected to immunohistochemical staining for the indicated 
molecules of interest including cytokeratin (CK, epithelial marker), Ki67 
(proliferation), endomucin (vasculature), α-sma (myofibroblasts), as 
well as αvβ6 and HER2 expression. Representative images are shown 
of the three tumors harvested for IgG and the combination treatment, 
where the greatest effect was observed. Scale bar in whole tumor 
images = 2000 μM, magnified images (x60) are of indicated region of 
interest (CK+ cells). Scale bar in x60 magnification images  =  20  μM. 
B) Bar graph of composition of xenografts (% CK+ cells = white bar, 
% necrotic area in black, and % stroma is in gray or blue) and his-
tograms of specific marker expression of xenografts shown in (A). 
Assessed and scored by two individuals (n = 3 individual tumors, error 
bars represent 95% confidence interval). *P  =  .05, **P  =  .01, ***P < 
.001 (relative to IgG, as determined by two-sided, one-way analysis of 
variance with Bonferroni Multiple Comparison Test [B, upper panel] 
and two-sided Student’s t-test [B, lower panel]). CK = pancytokeratin; 
HER2 = Human Epidermal Growth Factor Receptor 2; IgG =  immuno-
globulin; TRA = trastuzumab.
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combined blockade of αvβ6 and HER2 eradicated HER2-18 
tumors in all treated mice.
Tumors were allowed to reach 200 mm3 before commencing 
therapy. Figure 7B shows that, compared with IgG, monotherapy 
with 264RAD or trastuzumab slowed growth (both P = .002), which 
was again statistically significantly further reduced with combi-
nation therapy (P  =  .014 and P  =  .022, respectively), which com-
pletely suppressed growth of tumors (P < .001, compared to IgG). 
These mice were killed when their tumors reached the maximum 
size permissible (following Home Office regulations) (Figure 7C). 
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Figure  7. The effect of long-term (six-week) treatment of 264RAD in 
combination with trastuzumab on human xenograft MCF-7/HER2-18 
cell growth in SCID mice. Mice bearing human MCF-7/HER2-18 tumors 
were treated with IgG (square, solid line), 264RAD (triangle, dashed 
line, in line with TRA), trastuzumab (TRA) (square, dashed line), or 
264RAD+TRA (triangle on lower dashed line) (10 mg/kg; ip) twice 
weekly for six consecutive weeks. Data are presented as mean tumor 
volume (error bars represent 95% confidence interval, n > 5 mice/
group). Treatment commenced (indicated by arrows) when tumors were 
4 mm in any one dimension (A), and when tumors reached 200 mm3 (n 
> 6 mice/group) (B). C) Kaplan–Meier survival plot shows survival of 
mice from study of larger tumors shown in (B). D) Tumors from treated 
mice in (A) were analyzed by immunoblotting for indicated targets 
(combination therapy treated xenografts were eradicated, hence were 
unavailable for analysis). Actin immunoblot shows equal protein input. 
E) Histograms quantifying changes in protein expression levels from 
(D) (β-actin corrected). *P = .05, **P = .01, ***P < .001 (relative to IgG, 
or to treatment indicated by corresponding lines to the side of growth 
curves and above histograms). For tumor xenograft models, individual 
growth curves were plotted and a linear mixed model was used to test 
for differences between treatments. It was fitted by maximum likelihood 
using the nlme package in the statistical software R (R Development 
Core Team, 2010) 2.11.1. P values are from Wald tests. Survival of mice 
was measured using the Log-Rank test. All tests were two sided. 
HER2 = Human Epidermal Growth Factor Receptor 2; IgG =  immuno-
globulin; TRA = trastuzumab.
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Combination therapy improved survival statistically significantly 
better than monotherapy (P  =  .004 and P  =  .039, compared with 
264RAD and trastuzumab, respectively). No toxicity was observed 
in any mice for the duration of treatments as determined by change 
in body mass (>10% reduction), appearance or behavior.
Molecular Response of Breast Tumors to Long-term 
Combination Therapy
We confirmed monotherapy operated via similar molecular mech-
anisms to combination therapy by assessing protein expression in 
xenograft tissues treated for six weeks (Figure 7A). Reductions in 
β6, HER2, HER3, and T-Akt2 were observed (Figure 7, D and E), 
similar to the response of combination therapy after two weeks of 
therapy (Figure  4, D-G). Combination therapy eradicated xeno-
grafts prior to the end of this study, so no analysis of these tissues 
was possible.
Potential Mechanisms of 264RAD and Trastuzumab 
Therapy
Because αvβ6 activates TGFβ, we investigated the role of TGFβ in 
invasion and the effect of αvβ6 inhibition on invasion in the pres-
ence and absence of TGFβ ligand or receptor in vitro (Figure 4A). 
TGFβ did not contribute to Matrigel-invasive ability of breast can-
cer cells (Supplementary Figure 4A, available online).
Contrastingly, suppression of TGFβ signaling, measured by 
P-Smad2 reduction, occurred in BT-474 cells after two weeks of 
monotherapy with 264RAD or trastuzumab and was reduced fur-
ther by combination (Figure 4D). However, statistically significant 
reductions in P-Smad2 were only seen in HER2-18 after six weeks 
(Figure 7, D and E).
PI3K/Akt signaling has been implicated in HER2+ breast can-
cer progression, hence we knocked down Akt1 and Akt2 (Akt3 was 
not expressed, data not shown) and observed the effect on invasion 
in the Transwell and organotypic invasion assays. We discovered 
that Akt2, but not Akt1, was necessary for invasion of Matrigel 
and organotypic gels (Supplementary Figure 4, B and C, available 
online). Antibody-treated tumors for Akt2 protein showed that 
two-week combination therapy statistically significantly reduced 
Akt2 expression, whereas monotherapy had little effect. Thus, loss 
of Akt2, the isoform essential for invasion in 3/3 breast carcinoma 
cell lines, was associated with the improved in vivo efficacy of com-
bined αvβ6 and HER2 targeting vs monotherapy.
Discussion
This study shows conclusively that: 1)  upregulation of integrin 
αvβ6 in breast cancer is a poor prognostic factor linked with 
development of distant metastases; 2)  co-upregulation of αvβ6 
and HER2 identifies one of the worse prognostic sub-groups of 
breast cancer, because 5-year OS of the already poor progno-
sis HER2 subgroup (28) drops from 65.1% to 52.8% if αvβ6 is 
also expressed strongly; and 3)  the likely biological explanation 
for these clinical observations is that αvβ6 and HER2 cooperate 
(within the same molecular complex), the integrin αvβ6 mediat-
ing the invasive behavior of HER2-promoted cancer. Our data 
support the proposal that testing of biopsies for αvβ6 expres-
sion should become a routine immunopathological procedure to 
stratify women with breast cancer into this new ‘very-high-risk’ 
αvβ6-positive/HER2+ subgroup. The value of this stratification 
is that our study also suggests a promising therapeutic strategy for 
this high-risk subgroup.
Trastuzumab is the first line of therapy for women with HER2+ 
breast cancer, either as an adjuvant therapy for early stage breast can-
cer or in combination with chemotherapy for metastatic breast cancer 
(4,29). In 2012, more than 225 000 women developed breast cancer in 
the US, and 20% to 25% would have had HER2 overexpression (NIH 
statistics) and been likely to have received trastuzumab. However, 70% 
of these women will develop resistance, or naturally be resistant, to 
trastuzumab (6), meaning up to 39 375 American women will develop 
HER2+ breast cancers for which no specific therapies exist. Our data 
show that over 40% of these HER2+ women are also likely to express 
high levels of αvβ6. We suggest that antibody targeting of αvβ6 in 
these women may offer a therapeutic option, and our preclinical stud-
ies support this proposal. Our data show that in both trastuzumab-
sensitive and –resistant, HER2-overexpressing human breast cancer 
xenografts, simultaneous antibody targeting of αvβ6 (with 264RAD) 
and HER2 (with trastuzumab) statistically significantly improves the 
therapeutic effect of trastuzumab alone and statistically significantly 
increases survival.
The molecular mechanisms of how antibody-blockade can sup-
press or reduce breast cancer growth involve, in part, the changing 
of the tumor phenotype to a lower risk sub-type. In antibody-
treated tumors, there is consistent down-regulation of expression 
of αvβ6, HER2, and HER3, three receptors whose upregulation 
promotes breast cancer, reduces survival, and therefore drives 
metastasis (28). Even monotherapy targeting either αvβ6 or HER2 
suppressed αvβ6 expression, further suggesting that these two mol-
ecules are coregulated in breast cancer.
Combined αvβ6 and HER2 blockade was more effective than 
monotherapy at slowing or reducing tumor growth. We looked 
at signaling pathways implicated in αvβ6 and HER2 behavior to 
understand this effect.
We examined TGFβ signaling, because αvβ6 can activate latent 
TGFβ (15). Moreover, activated TGFβ promotes HER2 tumori-
genicity by increasing migration, invasion and metastasis (9–11,30). 
Again, only combination therapy statistically significantly reduced 
Smad2 in BT-474 tumors, whereas monotherapy was not statis-
tically significantly effective. In contrast, in trastuzumab-resistant 
tumors, reduction in TGFβ signaling was relatively poor.
Trastuzumab mediates anti-proliferative effects in HER2+ cells 
by facilitating HER2 degradation and downregulation of PI3-K/
Akt signaling (31,32). Our data demonstrate that after two weeks 
of antibody therapy, downregulation of Akt2, rather than TGFβ 
signaling, correlated more strongly with the enhanced tumor sup-
pression seen with combination therapy. However, this does not 
negate the likelihood that loss of TGFβ signaling, due to antibody-
blockade of αvβ6, contributes to tumor therapy and overall survival 
seen after six weeks of therapy.
Immunohistological analysis of the combination antibody-
treated tumors confirmed the loss of αvβ6 and HER2 and sug-
gested apoptosis as one mechanism to explain the loss of BT-474 
cells. However, combination therapy also dramatically changed 
the stroma into a less tumor-permissive environment, reducing 
vascular density and the number of tumor-associated fibroblasts 
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(myofibroblasts). Whether these changes are in part due to abro-
gating the ability of αvβ6 to activate TGFβ, which is pro-angio-
genic and produces myofibroblasts, must be determined.
Our study is not without limitations. Grade data was unavailable 
for the London cohort. No clinical data were available for response 
to trastuzumab therapy. The combination therapy was tested in 
only two cell lines in vivo and the anti-tumor effect observed herein 
cannot necessarily be guaranteed in other β6+HER2+ cell lines nor 
in patients with β6/HER2-amplified breast cancer.
In summary, we suggest that examining breast cancers for αvβ6 
expression should become standard practice, because high expression 
of αvβ6 identifies women with statistically significantly more hazard-
ous types of disease, especially those who are HER2+. In addition, 
our data show that antibody blockade of αvβ6 could offer an effective 
additional therapy for such women, possibly even those with tras-
tuzumab-resistant disease. The fact that human (264RAD; 33) and 
humanized (STX-100; 34) αvβ6-blocking antibodies are being devel-
oped for human use shows that αvβ6 targeted therapy of breast can-
cer is feasible and should be a major consideration for the near future.
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